Hubei Guangji Pharmaceutical(000952.SZ) has obtained the registration certificate for mecobalamin tablets.

15:54 12/02/2026

Guangji Pharmaceutical Co., Ltd. (000952.SZ) announced that they have recently received the "Drug Registration Certificate" for methycobal tablets approved and issued by the National Medical Products Administration. The approval of the methycobal tablet "Drug Registration Certificate" marks a significant progress in the company's product layout in the treatment of peripheral nervous system diseases, providing domestic patients with high-quality options for domestically produced medications.

Hubei Guangji Pharmaceutical (000952.SZ) announced that recently, the company has received the "Drug Registration Certificate" for methylcobalamin tablets approved and issued by the National Medical Products Administration. The approval of the Drug Registration Certificate for methylcobalamin tablets marks an important milestone for the company in the field of treatment for peripheral nerve diseases, providing high-quality domestic drug options for patients in China.

Lyon: First time covering TIANYU SEMI (02658) with an "outperform" rating, target price of HK$70.

HENG TAI (00197) issues profit warning, predicting a net loss of approximately HKD 33.4 million for the mid-term.

ANHUI EXPRESSWAY (00995): "25 Wan Tong V1" and "25 Wan Tong V2" will pay interest on March 3rd.

Lyon: First time covering TIANYU SEMI (02658) with an "outperform" rating, target price of HK$70.

HENG TAI (00197) issues profit warning, predicting a net loss of approximately HKD 33.4 million for the mid-term.

ANHUI EXPRESSWAY (00995): "25 Wan Tong V1" and "25 Wan Tong V2" will pay interest on March 3rd.